Featured News

ZED1227, an experimental drug was found to be able to prevent intestinal damage in a preliminary trial of 163 adults with celiac disease.

The CeDLara Study is for adults who have been diagnosed with celiac disease and are still experiencing symptoms despite following a gluten-free diet.

Latiglutenase is a dual enzyme investigational product designed to break down gluten in the stomach. Learn more about the trial and what this means for celiac disease patients.

Ukko, a startup focused on eradicating food allergies, intolerances, and sensitivities, has reached a promising stage in its effort to develop a gluten specifically designed for people with celiac disease.

9 Meters Biopharma, Inc., a clinical-stage company focused on rare and unmet needs in gastroenterology, announced their collaboration with the Celiac Disease Foundation to support clinical trial enrollment.

The Celiac Disease Foundation is proud to have been involved by recruiting patients essential for this trial’s success.

The ACeD Study is looking for volunteers with celiac disease to participate in a phase 1 clinical trial testing the investigational drug KAN-101.

We are pleased to share that CEO Marilyn Geller will be presenting as the Patient Advocate at the March 18-19 National Institute of Allergy and Infectious Diseases Accelerating Progress in Celiac Disease Workshop. We encourage you to register to attend this seminal virtual meeting.

The Senate Appropriations Committee has released their FY2021 funding recommendations, which includes report language directing NIH to support celiac disease research.

The Society for the Study of Celiac Disease (SSCD) has released a statement on the COVID-19 vaccination and its safety for celiac disease patients.